154 related articles for article (PubMed ID: 6239835)
1. Menogaril: a new anthracycline agent entering clinical trials.
McGovren JP; Nelson KG; Lassus M; Cradock JC; Plowman J; Christopher JP
Invest New Drugs; 1984; 2(4):359-67. PubMed ID: 6239835
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of menogaril in patients with advanced cancer.
Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
[TBL] [Abstract][Full Text] [Related]
4. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
Long HJ; Powis G; Schutt AJ; Moertel CG
Cancer Treat Rep; 1987 Jun; 71(6):593-8. PubMed ID: 2953414
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and disposition of menogaril (NSC 269148) in the rabbit.
Dodion P; Egorin MJ; Engisch KL; Bachur NR
Cancer Res; 1985 Nov; 45(11 Pt 1):5352-7. PubMed ID: 2932217
[TBL] [Abstract][Full Text] [Related]
7. Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology.
Wierzba K; Sugimoto Y; Matsuo K; Toko T; Takeda S; Yamada Y; Tsukagoshi S
Jpn J Cancer Res; 1990 Aug; 81(8):842-9. PubMed ID: 2144516
[TBL] [Abstract][Full Text] [Related]
8. Effects of 7-R-O-methylnogarol (menogaril) on L1210 cell progression in vitro and in vivo.
Adams EG; Bhuyan BK
Cancer Res; 1986 Dec; 46(12 Pt 1):6125-30. PubMed ID: 2946401
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor spectrum of TUT-7 on rat ascitic hepatoma].
Satoh H; Taguchi H; Yahagi S
Gan To Kagaku Ryoho; 1990 Feb; 17(2):287-91. PubMed ID: 2137321
[TBL] [Abstract][Full Text] [Related]
10. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
[TBL] [Abstract][Full Text] [Related]
11. The biochemical pharmacology of nogalamycin and its derivatives.
Li LH; Krueger WC
Pharmacol Ther; 1991; 51(2):239-55. PubMed ID: 1838416
[TBL] [Abstract][Full Text] [Related]
12. Comparative genotoxicity of adriamycin and menogarol, two anthracycline antitumor agents.
Bhuyan BK; Zimmer DM; Mazurek JH; Trzos RJ; Harbach PR; Shu VS; Johnson MA
Cancer Res; 1983 Nov; 43(11):5293-7. PubMed ID: 6225515
[TBL] [Abstract][Full Text] [Related]
13. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of menogaril and N-demethylmenogaril in a human tumor cloning assay.
Dodion P; Sanders C; Rombaut W; Rozencweig M; Kitt MM; Kenis Y; Klastersky J
Eur J Cancer Clin Oncol; 1986 Mar; 22(3):245-9. PubMed ID: 2940092
[TBL] [Abstract][Full Text] [Related]
15. The disposition of the new anthracycline antibiotic, menogarol, in mice.
Dodion P; Chang BK; Egorin MJ; Olman EA; Engisch KL; Bachur NR
Drug Metab Dispos; 1984; 12(3):365-70. PubMed ID: 6145565
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure.
Buckner JC; Edmonson JH; Ingle JN; Schaid DJ
Am J Clin Oncol; 1989 Oct; 12(5):384-6. PubMed ID: 2529759
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.
Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Piccart M; Tueni E; Joggi J; Kenis Y
Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1019-26. PubMed ID: 2970391
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).
Stephens RL; Goodman P; Crawford ED; Spicer CF; Lowe BA; Ahmann FR; Chapman R; Natale RB
Invest New Drugs; 1990; 8 Suppl 1():S69-71. PubMed ID: 2143177
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of oral menogaril administered on three consecutive days.
Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Joggi J; Kenis Y
Acta Oncol; 1988; 27(5):517-20. PubMed ID: 2974291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]